Please use this identifier to cite or link to this item:
|Title:||Mesenchymal stem cells-derived secretome and extracellular vesicles: perspective and challenges in cancer therapy and clinical applications||Authors:||Gemayel, Jack
El Hachem, Georges
|Affiliations:||Department of Medical Laboratory Sciences||Keywords:||Cancer therapy
Mesenchymal stem cell
|Issue Date:||2023-01-07||Publisher:||Springer||Part of:||Clinical and Translational Oncology||Abstract:||
Stem cell-based therapies have been foreshowed as a promising therapeutic approach for the treatment of several diseases. However, in the cancer context, results obtained from clinical studies were found to be quite limited. Deeply implicated in inflammatory cues, Mesenchymal, Neural, and Embryonic Stem Cells have mainly been used in clinical trials as a vehicle to deliver and stimulate signals in tumors niche. Although these stem cells have shown some therapeutical promises, they still face several challenges, including their isolation, immunosuppression potential, and tumorigenicity. In addition, regulatory and ethical concerns limit their use in several countries. Mesenchymal stem cells (MSC) have emerged as a gold standard adult stem cell medicine tool due to their distinctive characteristics, such as self-renewal and potency to differentiate into numerous cell types with lower ethical restrictions. Secreted extracellular vesicles (EVs), secretomes, and exosomes play a crucial role in mediating cell-to-cell communication to maintain physiological homeostasis and influence pathogenesis. Due to their low immunogenicity, biodegradability, low toxicity, and ability to transfer bioactive cargoes across biological barriers, EVs and exosomes were considered an alternative to stem cell therapy through their immunological features. MSCs-derived EVs, exosomes, and secretomes showed regenerative, anti-inflammatory, and immunomodulation properties while treating human diseases. In this review, we provide an overview of the paradigm of MSCs derived exosomes, secretome, and EVs cell-free-based therapies, we will focus on MSCs-derived components in anti-cancer treatment with decreased risk of immunogenicity and toxicity. Astute exploration of MSCs may lead to a new opportunity for efficient therapy for patients with cancer.
|URI:||https://scholarhub.balamand.edu.lb/handle/uob/6667||ISSN:||1699048X||DOI:||10.1007/s12094-023-03115-7||Open URL:||Link to full text||Type:||Journal Article|
|Appears in Collections:||Department of Medical Laboratory Sciences|
Show full item record
checked on Jun 4, 2023
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.